Drug intelligence / Profile preview

EVEGYN A

Development stage: Phase 1
Lead developer: Exeltis
Modality: Small Molecules
Administration: Intravaginal

Overview

EVEGYN A is a fixed-dose combination pharmaceutical drug designed for intravaginal administration, primarily indicated for the treatment of common vaginitis, including bacterial vaginosis and candidal vulvovaginitis. It combines the antifungal properties of fenticonazole nitrate, the antibacterial action of tinidazole, and the local anesthetic effect of lidocaine. This multi-component approach aims to eradicate both fungal and bacterial pathogens responsible for vaginitis while simultaneously providing symptomatic relief from associated discomfort. The drug has undergone Phase III clinical evaluation for its efficacy and safety.

Brand names: EVEGYN
Other names: EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Targets

DNAErgosterol

Beyond the preview

Go deeper on EVEGYN A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVEGYN A.

Explore the full profile